Amalgamated Bank Acquires 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Amalgamated Bank raised its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 756.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,324 shares of the company’s stock after acquiring an additional 15,301 shares during the quarter. Amalgamated Bank’s holdings in Protagonist Therapeutics were worth $780,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in PTGX. Vanguard Group Inc. lifted its stake in shares of Protagonist Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after purchasing an additional 39,055 shares during the last quarter. Seven Eight Capital LP lifted its stake in shares of Protagonist Therapeutics by 426.9% during the 2nd quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock worth $1,275,000 after purchasing an additional 29,810 shares during the last quarter. New York State Teachers Retirement System purchased a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth $1,107,000. Bank of New York Mellon Corp increased its position in Protagonist Therapeutics by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock valued at $7,079,000 after buying an additional 17,065 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in Protagonist Therapeutics during the 2nd quarter valued at about $2,112,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Protagonist Therapeutics news, CFO Asif Ali sold 14,203 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the transaction, the chief financial officer now owns 34,960 shares in the company, valued at approximately $1,555,370.40. This represents a 28.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the transaction, the director now owns 12,000 shares in the company, valued at approximately $540,000. This trade represents a 40.00 % decrease in their position. The disclosure for this sale can be found here. 5.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Protagonist Therapeutics in a research report on Monday, November 11th. JMP Securities cut their price objective on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. BTIG Research increased their price objective on Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. Finally, StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $53.57.

Protagonist Therapeutics Stock Up 0.2 %

Protagonist Therapeutics stock opened at $41.11 on Friday. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of 15.45 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 52 week low of $15.58 and a 52 week high of $48.89. The business’s 50-day moving average price is $45.64 and its 200 day moving average price is $38.50.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.